The present invention is directed to compounds of Formula (I),
and to pharmaceutically acceptable salts thereof, their synthesis, and their use as Raf inhibitors.
The present invention is directed to compounds of Formula (I),
and to pharmaceutically acceptable salts thereof, their synthesis, and their use as Raf inhibitors.
COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
申请人:Huang Shenlin
公开号:US20110306625A1
公开(公告)日:2011-12-15
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
Compounds and compositions as protein kinase inhibitors
申请人:Array BioPharma, Inc.
公开号:US10005761B2
公开(公告)日:2018-06-26
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.